UK Markets close in 7 mins
  • FTSE 100

    7,039.06
    +6.21 (+0.09%)
     
  • FTSE 250

    22,335.34
    +121.20 (+0.55%)
     
  • AIM

    1,238.75
    +4.66 (+0.38%)
     
  • GBP/EUR

    1.1619
    -0.0010 (-0.09%)
     
  • GBP/USD

    1.4190
    +0.0052 (+0.3704%)
     
  • BTC-GBP

    30,652.73
    -496.23 (-1.59%)
     
  • CMC Crypto 200

    1,212.05
    -41.09 (-3.28%)
     
  • S&P 500

    4,163.69
    +0.40 (+0.01%)
     
  • DOW

    34,255.04
    -72.75 (-0.21%)
     
  • CRUDE OIL

    65.91
    -0.36 (-0.54%)
     
  • GOLD FUTURES

    1,867.90
    +0.30 (+0.02%)
     
  • NIKKEI 225

    28,406.84
    +582.01 (+2.09%)
     
  • HANG SENG

    28,593.81
    +399.72 (+1.42%)
     
  • DAX

    15,387.42
    -9.20 (-0.06%)
     
  • CAC 40

    6,359.32
    -8.03 (-0.13%)
     

Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Verona Pharma plc
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three months ended March 31, 2021 on Thursday, April 29, 2021 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

To participate, please dial one of the following numbers and reference conference ID 7429971:

  • +1-888-317-6003 for callers in the United States

  • +1-412-317-6061 for international callers

A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.

For further information please contact:

Verona Pharma plc

US Tel: +1-833-417-0262

UK Tel: +44 (0)203 283 4200

Victoria Stewart, Director of Communications

info@veronapharma.com

Argot Partners
(US Investor Enquiries)

Tel: +1-212-600-1902
verona@argotpartners.com

Kimberly Minarovich / Michael Barron

Optimum Strategic Communications
(International Media and European Investor Enquiries)

Tel: +44 (0)203 950 9144
verona@optimumcomms.com

Mary Clark / Eva Haas / Shabnam Bashir

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.